Unknown

Dataset Information

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment.


ABSTRACT:

Purpose

U.S. Food and Drug Administration (FDA) recommended telavancin dosing is based on total body weight (TBW) but lacks adjusted regimens for obese subjects with varying renal function. Our aim was to develop a physiologically based pharmacokinetic (PBPK) model of telavancin to design optimized dosing regimens for obese patients with hospital-acquired pneumonia (HAP) and varying renal function.

Methods

The PBPK model was verified using clinical pharmacokinetic (PK) data of telavancin in healthy populations with varying renal function and obese populations with normal renal function. Then, the PBPK model was applied to predict the PK in obese HAP patients with renal impairment (RI).

Results

The fold error values of PK parameters (AUC, Cmax, Tmax

SUBMITTER: Wu W 

PROVIDER: S-EPMC7808764 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature